Amgen asks Supreme Court to take up its high-profile PCSK9 patent case against Sanofi and Regeneron

After Amgen earlier this year suffered a third consecutive loss in its high-profile PCSK9 patent feud with Sanofi and Regeneron, the company faced two choices: appeal further or drop the issue.

Not content to play sitting duck, Amgen has asked the Supreme Court to step in and review the case.